>>Signaling Pathways>> GPCR/G protein>> TSH Receptor>>Org41841

Org41841

Catalog No.GC32423

Org41841은 황체형성 호르몬/융모막 성선 자극 호르몬 수용체(LHCGR)와 갑상선 자극 호르몬 수용체(TSHR)의 부분 효능제이며 EC50이 각각 0.2 및 7.7μM입니다.

Products are for research use only. Not for human use. We do not sell to patients.

Org41841 Chemical Structure

Cas No.: 301847-37-0

Size 가격 재고 수량
1mg
US$214.00
재고 있음
5mg
US$342.00
재고 있음
10mg
US$540.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Org41841 is a partial agonist of both luteinizing hormone/chorionic gonadotropin receptor (LHCGR) and thyroid-stimulating hormone receptor (TSHR) with EC50s of 0.2 and 7.7 μM, respectively.

Functional assays demonstrate that Org41841 is a partial agonist of both luteinizing hormone/chorionic gonadotropin receptor (LHCGR) and thyroid-stimulating hormone receptor (TSHR) with EC50s of 0.2 and 7.7 μM, respectively. Treatment of L570F with Org41841 reveals an improved EC50 of 800 nM. M9 responds to Org41841 with an improved EC50 of 2700 nM and a greatly improved efficacy for signaling to 99% of the maximal value observed for thyroid-stimulating hormone (TSH) stimulation of thyroid-stimulating hormone receptor (TSHR)[1].

[1]. Holger Jaschke, et al. A low molecular weight agonist signals by binding to the transmembrane domain of thyroid-stimulating hormone receptor (TSHR) and luteinizing hormone/chorionic gonadotropin receptor(LHCGR). J Biol Chem. 2006 Apr 14;281(15):9841-4.

리뷰

Review for Org41841

Average Rating: 5 ★★★★★ (Based on Reviews and 40 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Org41841

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.